NBTXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NNBXF
Nanobiotix S.A.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$21.08−0.22 (-1.03%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2017 to 2025
Operating margin
-33.2%+1417.0 pts over 5 years
Net margin
-73.5%+1263.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | – | +89.7% | +67.0% | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on assets | – | -35.3% | -35.5% | |
| Current ratio | – | 6.58 | 1.09 | |
| Interest coverage | – | 13.8× | -0.7× | |
| Capex to revenue | – | 3.8% | 1.7% | |
| Diluted shares | – | 24.39B | 47.82B |
Where the cash went
Fiscal 2021 to 2025, five years combined
Nanobiotix generated €132.42M from operations and spent €2.03M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
€132.42M
Used
€2.03M
Capital expenditure€2.03M100%Dividends€00%Share buybacks€00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-€23.96M
- Cash generatingOperating cash flow above zero-€33.42M
- Return on assets improvedROA up on the prior year-72.6% → -35.5%
- Earnings backed by cashOperating cash flow above net income-€33.42M vs -€23.96M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.04 → 1.09
- No dilutionShare count did not rise47.27B → 47.82B
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose-0.08 → 0.48